Advertisement

Topics

Novartis heart-failure med Entresto cuts A1c

11:07 EDT 20 Mar 2017 | BioSpectrum

Biospectrum

id-100255399

Entresto is indicated to reduce the risk of cardiovascular (CV) death and hospitalization for HF in patients with chronic HF (NYHA Class II-IV) and reduced ejection fraction [Read more]

Original Article: Novartis heart-failure med Entresto cuts A1c

NEXT ARTICLE

More From BioPortfolio on "Novartis heart-failure med Entresto cuts A1c"

Quick Search
Advertisement
 

Relevant Topic

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...